ImmuneOncia Therapeutics

IPO

Changing the Standard of cancer treatment by bringing Korea's 1st immuno-oncology drug

Public · Seoul, South Korea · Founded 2016 · $51.0M raised

Headquarters
Seoul
Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$51.0M
Last Round
$18.0M Series BJan 2021
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

ImmuneOncia Therapeutics is a South Korean immuno-oncology biopharmaceutical company focused on developing novel immunotherapies for cancer patients worldwide. Founded in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in antibody engineering and drug development to create immune checkpoint inhibitors and combination therapies. Its lead asset IMC-001 (danburstotug), a PD-L1 antibody, has shown strong clinical results including three-year survival rates above 80% in perioperative settings across gastric, esophageal, and liver cancers. The company publicly listed on KOSDAQ in 2025.

Summary

ImmuneOncia Therapeutics is a Biotech company based in Seoul, South Korea, founded in 2016. It has raised $51.0M in total across 2 rounds, most recently a $18.0M Series B round in Jan 2021. Investors include Paratus Investment and Premier Inc..

Funding History

IPOMay 2022
$24.0M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ImmuneOncia Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/immuneoncia-therapeutics"><img src="https://indexed.vc/api/badge/company/immuneoncia-therapeutics" alt="ImmuneOncia Therapeutics on Indexed.vc" width="260" height="76" /></a>